Literature DB >> 31481165

Magnetoencephalography applied to the study of Alzheimer's disease.

David López-Sanz1, Ricardo Bruña2, Jaisalmer de Frutos-Lucas3, Fernando Maestú4.   

Abstract

Magnetoencephalography (MEG) is a relatively modern neuroimaging technique able to study normal and pathological brain functioning with temporal resolution in the order of milliseconds and adequate spatial resolution. Although its clinical applications are still relatively limited, great advances have been made in recent years in the field of dementia and Alzheimer's disease (AD) in particular. In this chapter, we briefly describe the physiological phenomena underlying MEG brain signals and the different metrics that can be computed from these data in order to study the alterations disrupting brain activity not only in demented patients, but also in the preclinical and prodromal stages of the disease. Changes in non-linear brain dynamics, power spectral properties, functional connectivity and network topological changes observed in AD are narratively summarized in the context of the pathophysiology of the disease. Furthermore, the potential of MEG as a potential biomarker to identify AD pathology before dementia onset is discussed in the light of current knowledge and the relationship between potential MEG biomarkers and current established hallmarks of the disease is also reviewed. To this aim, findings from different approaches such as resting state or during the performance of different cognitive paradigms are discussed.Lastly, there is an increasing interest in current scientific literature in promoting interventions aimed at modifying certain lifestyles, such as nutrition or physical activity among others, thought to reduce or delay AD risk. We discuss the utility of MEG as a potential marker of the success of such interventions from the available literature.
© 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Electrophysiology; Functional connectivity; Lifestyle; Magnetoencephalography; Mild cognitive impairment; Power; Subjective cognitive decline

Mesh:

Year:  2019        PMID: 31481165     DOI: 10.1016/bs.pmbts.2019.04.007

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  3 in total

Review 1.  Therapy for Alzheimer's disease: Missing targets and functional markers?

Authors:  Milan Stoiljkovic; Tamas L Horvath; Mihály Hajós
Journal:  Ageing Res Rev       Date:  2021-03-09       Impact factor: 11.788

2.  Alterations in resting-state network dynamics along the Alzheimer's disease continuum.

Authors:  D Puttaert; N Coquelet; V Wens; P Peigneux; P Fery; A Rovai; N Trotta; N Sadeghi; T Coolen; J-C Bier; S Goldman; X De Tiège
Journal:  Sci Rep       Date:  2020-12-15       Impact factor: 4.379

3.  Age and APOE genotype affect the relationship between objectively measured physical activity and power in the alpha band, a marker of brain disease.

Authors:  Jaisalmer de Frutos-Lucas; Pablo Cuesta; Federico Ramírez-Toraño; Alberto Nebreda; Esther Cuadrado-Soto; África Peral-Suárez; David Lopez-Sanz; Ricardo Bruña; Silvia Marcos-de Pedro; María Luisa Delgado-Losada; Ana María López-Sobaler; Inmaculada Concepción Rodríguez-Rojo; Ana Barabash; Juan Manuel Serrano Rodriguez; Simon M Laws; Alberto Marcos Dolado; Ramón López-Higes; Belinda M Brown; Fernando Maestú
Journal:  Alzheimers Res Ther       Date:  2020-09-22       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.